ReviewSchizophrenia bulletin2008
Methodological issues in current antipsychotic drug trials.
Review in Schizophrenia bulletin, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Clinical trial design in non-invasive brain stimulation psychiatric research.International journal of methods in psychiatric research · 2011Pooled it
- Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology.PloS one · 2010Pooled it
- What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "real-world" 2-year follow-up trial.European archives of psychiatry and clinical neuroscience · 2020Trial
- Trial
- Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial.The lancet. Psychiatry · 2018Trial
- Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study.BMC psychiatry · 2013Trial
- Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial.BMC psychiatry · 2011Trial
- Comparative cardiometabolic safety and effectiveness of aripiprazole in people with severe mental illness: A target trial emulation.PLoS medicine · 2025Observational
- Targeted Treatment of Schizophrenia Symptoms as They Manifest, or Continuous Treatment to Reduce the Risk of Psychosis Recurrence.Schizophrenia bulletin · 2024Article
- Clinical Outcome Assessment Instruments in Schizophrenia: A Scoping Literature Review with a Focus on the Potential of Patient-reported Outcomes.Innovations in clinical neuroscience · 2023Article
- Medication Gaps and Antipsychotic Polypharmacy in Previously Hospitalized Schizophrenia Patients: An Electronic Cohort Study in Three Canadian Provinces.Frontiers in psychiatry · 2022Article
- α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future.Neuropharmacology · 2020Review
- The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia.Dialogues in clinical neuroscience · 2018Article
- The Representativeness of Participants With Severe Mental Illness in a Psychosocial Clinical Trial.Frontiers in psychiatry · 2018Article
- Influence of different second generation antipsychotics on the QTc interval: A pragmatic study.World journal of psychiatry · 2016Article
- Pharmaceutical care in a long-stay psychiatric hospital.European journal of hospital pharmacy : science and practice · 2016Article
- Antipsychotic Maintenance Treatment: Time to Rethink?PLoS medicine · 2015Article
- Time to discontinuation of antipsychotic drugs in a schizophrenia cohort: influence of current treatment strategies.Therapeutic advances in psychopharmacology · 2014Article
- Evaluation of different approaches for confounding in nonrandomised observational data: a case-study of antipsychotics treatment.Community mental health journal · 2014Article
- Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.The European journal of health economics : HEPAC : health economics in prevention and care · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Every year numerous reports on antipsychotic drug trials are being published in neuropsychiatric journals, adding new information to our knowledge in the field. The information however is often hard for the reader to interpret, sometimes contradictory to comparable available studies and leaves more questions open than it actually answers. Although the overall quality of the studies is rather good, there are manifold options for further improvement in the conception, conduct, and reporting of antipsychotic drug trials. In this survey, we address methodological challenges such as the limited generalizability of outcomes due to patient selection and sample size; the vague or even lacking definition of key outcome parameters such as response, remission or relapse, insufficient blinding techniques, the pitfalls of surrogate outcomes and their assessment tools; the varying complex statistical approaches; and the challenge of balancing various ways of reporting outcomes. The authors present practical examples to highlight the current problems and propose a concrete series of suggestions on how to further optimize antipsychotic drug trials in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.